Bal Pharma Limited (BALPHARMA) fundamentals
Bal Pharma Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as BALPHARMA (ISIN INE083D01012). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Bal Pharma Limited does
Bal Pharma Limited is a pharmaceutical company engaged in the manufacturing and selling of pharmaceutical products. The Company is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). It specializes in prescription drugs, generic & OTC products, intravenous infusion, and bulk actives. The Company offers a range of APIs including antihistamine, platelet inhibitor, anti-diabetic, anticonvulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, and others. It also offers a range of formulations covering dosage forms-tablets, capsules, syrups, suspensions, IV infusions, ophthalmics, creams and ointments to various semi-regulated markets. The API products are being exported to Japan, Australia, Spain, the United Kingdom, Canada, Nigeria, Iceland, Slovenia, Romania, Brazil, Pakistan, Germany, South Africa, Serbia, Taiwan, Malaysia, Thailand, among others.
Valuation and market data
| Last close | ₹107.42 |
|---|---|
| Market capitalisation | ₹171 crore |
| Enterprise value | ₹208 crore |
| P/E (TTM) | 0.00 |
| Price to book | 2.21 |
| Price to sales (TTM) | 0.51 |
| Book value per share | ₹48.54 |
| Dividend yield | 111.71% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon May 08 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹314 crore | ₹6 crore | ₹6 crore | 0.00 |
| Mar 2025 | ₹305 crore | ₹5 crore | ₹7 crore | 4.54 |
| Mar 2024 | ₹342 crore | ₹9 crore | ₹7 crore | 4.96 |
| Mar 2023 | ₹305 crore | ₹5 crore | ₹3 crore | 1.67 |
| Mar 2022 | ₹286 crore | ₹9 crore | ₹6 crore | 3.79 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 50.9% |
|---|---|
| Foreign institutions (FII) | 0.1% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 49.0% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.